GLOBAL OFFERING
JW (Cayman) Therapeutics Co. Ltd (02126)
−
Cover
−
Important
−
Expected Timetable
−
Contents
−
Summary
−
Definitions
−
Glossary of Technical Terms
−
Forward-looking Statements
−
Risk Factors
−
Waivers from Strict Compliance with the Listing Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance
−
Information about this Prospectus and the Global Offering
−
Directors and Parties Involved in the Global Offering
−
Corporate Information
−
Industry Overview
−
Regulatory Overview
−
History, Development and Corporate Structure
−
Contractual Arrangements
−
Business
−
Financial Information
−
Share Capital
−
Cornerstone Investors
−
Substantial Shareholders
−
Directors and Senior Management
−
Connected Transactions
−
Future Plans and Use of Proceeds
−
Underwriting
−
Structure of the Global Offering
−
How to Apply for the Hong Kong Offer Shares
−
Appendix I - Accountants' Report
−
Appendix II - Unaudited Pro Forma Financial Information
−
Appendix III - Accountants' Report of Syracuse Biopharma (Hong Kong) Limited
−
Appendix IV - Summary of the Constitution of the Company and Cayman Companies Law
−
Appendix V - Statutory and General Information
−
Appendix VI - Documents Delivered to the Registrar of Companies and Available for Inspection
−
Back Cover